Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly & Co. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with unparalleled accuracy. Back To Top
Prediction: This Will be Eli Lilly's Next Big Move.
Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring sales thanks to its dominance in the high-growth weight loss drug market. This is thanks to Lilly's dominance in the billion-dollar weight loss drug market.
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 584.52% and currently trading at $905.00. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,
Eli Lilly & Co. stock rises Thursday, still underperforms market
Shares of Eli Lilly & Co. LLY advanced 1.11% to $915.04 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 and the Dow Jones Industrial Average DJIA rising 1.
6h
Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade)
Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...
2d
on MSN
Eli Lilly and Company (LLY): Hedge Funds Are Bullish On This Counter Cyclical and Defensive Stock to Invest In
We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...
10d
on MSN
Eli Lilly’s new CFO is a 23-year company veteran—showing how pharma firms rely on a ‘deep bench of qualified talent’
Ashkenazi was CFO at Lilly from 2021 until leaving the company this summer. Like Montarce, she joined Lilly in 2001. During ...
2d
on MSN
This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk's and Eli Lilly's Weight Loss Treatments
In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...
2d
Eli Lilly urges court to toss $183 mln Medicaid fraud judgment
Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...
Ibj.com
2d
Eli Lilly request records of people who took copies of its weight-loss drug
The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...
13d
Moderna, Eli Lilly, and other drug firms in Greater Boston have become galleries for disadvantaged artists
Many of the industry’s glitzy new buildings are showcasing impressive artwork by artists dealing with homelessness or living ...
USA Today
4d
New eczema drug from Eli Lilly receives FDA approval for children and adults
On Friday, the U.S. Food and Drug Administration approved
Eli
Lilly
's eczema drug for use in adults and children 12 and ...
6h
Eli Lilly’s Competitive Edge in Weight Loss Medication Market Bolstered by Orforglipron’s Promising Trial Results
Deutsche Bank analyst James Shin has maintained their bullish stance on LLY stock, giving a Buy rating on September 16. James Shin has given ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Novo Nordisk
EBGLYSS
Feedback